|
MaxWLX Weight Loss
LEPTIN & 'THE MESSAGE':
The real science of weight management
Losing weight and keeping it off has been the bane of millions of
people concerned about their health for time in memoriam. This is
why experts, like Dr. Michael Rosenbaum of the Columbia University
College of Physicians and Surgeons have stated:
"Anybody who has ever lost weight and tried to keep it off
knows… that you never lose as much weight as you think you should.
And if you manage to lose as much weight as you'd like to, it's
very, very difficult to keep it off."
But why is shedding excess weight so difficult; and why is keeping
it off an even greater challenge? Why, as Professor Gary Wittert
stated, is "The natural history of weight loss, weight regain."
This question remained seemingly unanswerable until 1994, when
scientists at the University of Rochester discovered a Master
Hormone called LEPTIN and the dysfunctional message it sends to
the brain that controls appetite and fat storage. Soon after its
discovery, scientists postulated that it is Leptin and -- what is
now simply referred to as -- THE MESSAGE that could determine
if you are fit, or fat!
Leptin, which is produced by fat cells, sends THE MESSAGE to the
brain, telling it whether enough fat is stored in the body and if
it's time to stop eating... But as the human body has evolved,
Leptin has stopped working properly. For most people, this
manifests itself in Leptin sending a continuous, yet erroneous
message to the brain indicating, "your hungry, keep eating, and
store more fat." It is this dysfunctional and perilous message
that results in the body hoarding away even more fat than is
necessary. Simply put, the failure of Leptin and its message is
"sabotaging people's best efforts" at weight loss.
In very simple terms, the higher the leptin levels, the greater
the storage of fat. Correspondingly, if leptin levels can be
lowered, then the body is signaled to release stored and dietary
fat for other purposes, most predominately as energy.
Dr. Philipp E. Scherer may have said it best, when he stated in an
article in the New York Times that:
"The discovery of Leptin established the fat-to-brain
communication axis.”
The discovery of Leptin is so significant that it has been
referred to as:
"... the most significant hormone there is in understanding the
function of the human body."
…and
"…the key that unravels the great mysteries of health."
(Mastering Leptin. Richards. Pg.44)
In view of the impact of Leptin and THE MESSAGE on weight
management, and the link between excess body weight and a host of
pathologies – diabetes, cardiac disease, osteoarthritis, and
metabolic syndrome – the preceding proclamations about Leptin are
not surprising. What is surprising is that finding a solution to
the Leptin conundrum has proved to be very difficult, and neither
continuous exercise nor diets function to lower leptin levels and
fix THE MESSAGE. In fact, popular calorie restricted diets places
the body in a moderate mode of starvation, with the result being
the body becoming more efficient at storing fat and placing the
Leptin messaging to the brain in an even greater state of
upheaval.
To that end, virtually all diets or appetite suppressants rely on
calorie manipulation, a technique that allows for short term
"weight loss" (water and lean muscle loss) and more weight gain
(fat) in the future. Because weight loss is predominantly lean
muscle loss, your fat to muscle ratio rises and you have setup
your body to become very efficient at storing fat. Any weight
management measure – most diets and over the counter weight loss
pills – that places the body in a starvation state, will be
ineffective in managing weight over the long-term. It's why
Michael Steelman, an obesity specialist and former president of
the American Society of Bariatric Physicians stated:
"Taking these pills is like having brain surgery from someone
who trained via a correspondence course."
NOW EVERYBODY IS GETTING
THE MESSAGE!
It is now considered scientific gospel that THE MESSAGE will, for
most people, determine if they are fit or fat! As obesity expert
Dr. Louis Aronne stated in a CBS News 48 hours TV report:
“Over time, the body loses control of weight…. and you just
can't control your weight, because you're not getting the right
messages from your body telling you how much fat is to be stored."
This is commonly known as Leptin Dysfunction, and Scientists and
Doctors, such as metabolic specialist, Doctor Ron Rosedale, agree
that,"Only when Leptin sensitivity is restored, will you stop
storing excess fat and instead, start burning it off. Best of all,
your hunger will be controlled, you will not have food cravings,
and you will have a trim, well-toned, and healthy body."
Leptin and THE MESSAGE has become so important in understanding
weight gain and the unhealthy pathologies connected with excess
body weight -- diabetes, heart disease, osteoarthritis and
metabolic syndrome -- that it has been featured in over 8000
published studies, and covered in countless newspaper and magazine
articles. As well a litany of TV shows, including recent coverage
on Oprah ,and a Special Segment hosted by Katie Couric on the CBS
Evening News. In fact, fixing Leptin Dysfunction has been
declared:
"THE HOLY
GRAIL OF WEIGHT LOSS!"
The pursuers of this coveted scientific grail include Big Pharma,
Biotech firms, and major research Universities the world over, all
engaged in what CBS News reported as a:
"A race on to develop that "magic bullet" medication that will
manipulate leptin, in the hope that not only will people lose more
weight, but they'll keep it off."
The Waiting Is Over!
Unlike any other
over-the-counter weight loss product, MAXWLX™ is steeped in
science. That's because MAXWLX™ was formulated in response to the
breakthrough scientific discovery of the hormone Leptin. MAXWLX'™
pedigree, efficacy and the veracity of its claims are peerless,
particularly when contrasted against other over-the-counter weight
loss ingestible products.
That's because MAXWLX™ was researched and developed for more than
7 years at the University of Minnesota; the formula was awarded
TWO U.S. Patents (Patent No.: 6,899,892 awarded on 5-31-05)
covering 29 leptin, fat-reducing and body composition structure
function claims; and MAXWLX™ was rigorously tested in Double Blind
CLINICAL TRIALS at the renowned UNIVERSITY OF CONNECTICUT HUMAN
PERFORMANCE LAB. This type of pedigree is simply unheard for an
over-the-counter weight loss product!
Most importantly though, MAXWLX™ works! That's because MAXWLX™
provides a breakthrough resolution for lowering leptin levels. By
assisting in regulating Leptin and THE MESSAGE, MAXWLX™ naturally
suppresses appetite and converts stored and dietary fat into
energy and other metabolic purposes. By targeting Leptin and
THE MESSAGE that stimulates the release of excess stored body fat,
MAXWLX™ assists in preserving lean muscle mass for improved body
composition.
MAXWLX™ is comprised of a combination of patented, high viscosity
polysaccharides and esterified fatty acid carbons that work
together to successfully reduce fat on both a short-term and, more
importantly, long-term basis. Although it is always recommended
to eat sensibly, MAXWLX™ is exceptionally effective at reducing
fat independent of dietary habits. High leptin levels cause
fat to accumulate, as well as metabolism and energy levels to run
slow. In evolutionary times, for survival purposes, it was
necessary to store fat and have high levels of leptin. Today, high
leptin levels are unnecessary – with a fast food restaurant on
virtually every corner, and no dearth of food, starvation is no
longer an issue for most. MAXWLX™ safely and effectively lowers
leptin levels and keeps leptin balanced, and at healthy low levels
so that stored fat is continuously being used as energy.
To bolster the effects of MAXWLX™ [Company X] has added CELADRIN™
-- a patented and proprietary ingredient in its own right -- to
the MAXWLX™ formula. CELADRIN™ is a cetylated fatty acid that has
also been clinically studied as a stand-alone compound. CELADRIN™
has been proven to be extremely efficacious in reducing and
dampening systemic inflammation, so much so, that it has been
chronicled in the Journal of Rheumatology. It is a scientific fact
that inflammation and the dangerous chemicals produced in
connection thereto is a corollary of obesity and excess fat
storage. The inflammation resulting from excess fat is considered
by leading scientists to be responsible for a number of metabolic
and other health problems, including without limitation, obesity,
heart disease, diabetes and accelerated aging. The inclusion of
CELADRIN™ in the MAXWLX™ formula serves to reduce the inflammation
attributable to excess fat and, as such, the possible onset of
these dangerous maladies.
PREPARE FOR
QUICK RESULTS!
MAXWLX™ generally takes 2 – 4 weeks to lower leptin, and to
produce the noticeable signs of reduction of body fat. After 4
weeks of use, MAXWLX™ goes into overdrive and accelerates the
reduction of stored fat – independent of your dietary habits.
Prior to this 2 – 4 week period, you feel more energetic as leptin
levels are being lowered and continuously signaling the body to
use the stored and dietary fat as energy. The most noticeable
results are the reduction of fat where it is often stored -- hips,
thighs, waist, buttocks, and abdomen. Since MAXWLX™ targets
body fat and not lean muscle mass, the overall improvement in body
composition – defined as the ratio of body fat: lean muscle mass –
is glaring. The body will look more fit, toned and healthy.
This is the true
cornerstone of healthy weight loss and weight management, and is
in stark contrast to other weight loss supplements which put the
body in starvation mode and cause the body to consume lean muscle
for energy. The degradation of lean muscle and the effects of
the heavy stimulant content in these products often result in
users of these inefficacious products appearing unhealthy. This is
irrespective of any weight loss, which inevitably will be put back
on, and then some.
MAXWLX™ users, on the other hand, look leaner and fitter and have
sustained increased energy without relying upon harmful and
addictive stimulants. That's because there are no stimulants in
MAXWLX™. The increased energy comes from the excess stored body
fat being released back into the system. With no known side
effects, no stimulants and no harmful ingredients, perhaps the best
attribute of MAXWLX™ is that it can be taken for life… to improve
our quality of life!
MAXWLX™ is truly a weight management solution without peer. It
is not a quick fix like other products. It was developed and
tested at legitimate, reputable institutions over a long term so
that it would work over the long term. Unlike other products,
MaxWLX was actually developed in response to a real scientific
finding, and a biological phenomenon: the Leptin hormone and THE
MESSAGE it sends to the brain that controls appetite and fat
storage.
Consequently, MAXWLX™ is the only non-prescription weight loss
supplement that provides a real scientific solution for what has
become a veritable global epidemic – excess weight and obesity.
There are scores of people who struggle with attaining and
maintaining a healthy body weight and suffer from the immeasurable
negative health consequences that follow. MAXWLX™ is the first and
only natural weight loss product that has been researched and
developed, and rigorously tested in response to the true science
of weight loss.
Consequently, the maker of MAXWLX™ firmly believe that MAXWLX™ is
the only over-the-counter weight loss product that can
legitimately claim to be a solution for an ever burgeoning market.
PATENTED METHOD
FOR REDUCING BODY FAT
MaxWLX™ is a safe and natural complex of plant-based
polysaccharides and esterified fatty acids that have been shown to
reduce stored body fat and enhance weight loss. The improvement in
body composition and percent of body fat is achieved through the
interaction between the adipose tissue, brain and liver to control
serum leptin.
MaxWLX™ is a unique, proprietary blend that elicits a
time-dependent transit through the gastro-intestinal tract. It is
this time-dependent transit, which elicits the signal to regulate
leptin levels. Leptin serves as a regulator of body fat storage
by modulating satiation, glycemic control and metabolism.
Patented research from the University of Minnesota shows that
reductions in serum leptin correlate with lower regional body fat
and total body fat. MaxWLX™ matches up to US Patent No.: 6,899,892
in which the invention provides a method and composition for
reducing the level of leptin in the bloodstream, and
correspondingly reduction in the percentage of body fat. The
patent also claims sufficient reductions in the level of serum
leptin in the bloodstream to beneficial or efficacious levels in
approximately 3 to 6 weeks.
MaxWLX™ also enhances cell membrane stability for improved
cellular communication between the liver and adipose tissues for
enhanced fatty acid utilization, leading to regional fat loss. In
addition, modulation of membrane-based inflammatory markers helps
to reduce the inflammatory component of fat gain.
MaxWLX™ was clinically studied in an 8 week double blind, placebo
controlled trial at the University of Connecticut Human
Performance Laboratory, Storrs, CT 06269. The results of the study
were released on 12/06.
MaxWLX™ containing products from [Company X] have the attached
rights of employing the patent number on labels and brochures. At
efficacious levels, suggested structure-function or marketing
statements may include the following:
Assists in promoting fat loss (Supported by US Patent 6,899,892
and references 1, 2 and 3).
Assists in promoting a lower percentage of body fat (Supported by
US Patent 6,899,892 and references 1, 2, 3 and 4).
Promotes the reduction of stored fat by increasing fatty acid
utilization in the fat cell (Supported by references 4 and 5).
Promotes the reduction of fat and an enhanced muscle to fat ratio
(Supported by references 1, 2, 3 and 4).
Promotes the regulation of energy balance allowing for improved
mental energy (Supported by references 6 and 7)
Extra Information:
Referenced Studies
DRUG FORMULATIONS IN THE WEIGHT LOSS MARKET
The information outlined in this white paper reviews the current
state of medications available for the treatment of obesity for
comparison to a new product from [Company X]. This product is
called, MaxWLX™, and is a proprietary formulation specifically
developed for the purpose of lowering body fat in individuals
suffering from being overweight or obese. Moreover, the failure of
most dietary supplement products for helping the consumer lose
appreciable body weight and body fat and to offer life time
reductions plus the limitations of current medications to address
obesity as addressed below; offers an excellent opportunity for
MaxWLX™ to achieve success in the US and global distribution
channels.
The leading drug candidates are Rimonanbant, Sibutramine and
Orlistat™ that are currently on the market have different and
varied responses and side effects. As reported by Bray and Ryan;
over a 2 to 4 year period these medications averaged weight loss
of 8%-10% with the placebo contributing 4-6% of that total. Thus,
the net body weight loss is around 4% to 6% with these
medications. The authors underscore that weight maintenance is
maintained as long as the adherence to the medication is
continued.
Rimonabant has the best safety profile of these available drugs.
Nausea and gastrointestinal symptoms are the main reported
findings. Sibutramine elicits a rise in blood pressure and heart
rate that may offer significant downside to a number of patients.
Orlistat™ or its consumer brand, Alli™, induce steatorrhea as the
principal side effect with anal leakage an extenuating factor for
most individuals stopping treatment.
A recent study out of Canada reports the long-term effect of
Orlistat™ and Sibutramine on patient persistence. 17,000
individuals on Orlistat™ and 3500 on Sibutramine were studied (2).
For both Orlistat™ and Sibutramine; only 10% of the individuals
were able to maintain on the medication at 1 year; and a low 2%
after 2 years. The authors concluded that these two drugs offered
very poor long-term persistence rates. One can conclude that these
drugs would offer very limited help for individuals trying to loss
significant amounts of body weight and body fat; and to maintain
those losses over time.
If we are to compare the results of the University of Connecticut
study on the MaxWLX™ blend, a recent study from the University of
Kentucky offers interesting findings that are consistent with
previous literature (3). A multi-center trial was conducted using
a standard dose of Orlistat™ (60 mg; 3 times per day). Overweight
individuals were followed for 16 weeks. The authors reported that
using an intent to treat analysis the Orlistat™ group lost
significantly more weight than placebo (3.05 vs. 1.90 kg). But,
that when those individuals that actually stayed on the medication
for the full 16 weeks the following results were reported (Orlistat™
– 4.8 vs. 3.1 kg; p < 0.001). In comparison, those individuals
consuming MaxWLX™ experienced a reduction in body weight of 9.2 kg
versus 5.4 for the placebo group after only 8 weeks. While
this comparison reflects only one completed study on MaxWLX™ it
does lend support for the belief that MaxWLX™ is a viable option
to these current medications.
The results induced by these medications are modest at best ,and
generally reflect only changes in body weight. There are few, if
any, studies done reporting body composition changes after taking
medications. However, there is one viable study published looking
at body composition changes using Orlistat™. In this study
Orlistat™ was compared to surgical intervention in individuals
(4). After 6 months; both the surgical and Orlistat™ groups had
significant and appreciable reductions in body fat (-10.1 kg
versus -11.4 kg) while at the same maintaining fat free mass or
skeletal tissue. Interestingly, individuals who stayed on the
Orlistat™ treatment for 24 months only experienced a loss of - 4.4
kg compared to the surgical intervention of -15.9 kg. The
subjects in the University of Connecticut study lost -9.8 kg of
body fat after 8 weeks with the placebo losing -5.5 kg. The
subjects in both studies were consuming a moderately restricted
diet while the Connecticut groups were doing matched exercise and
nutritional programming.
As opposed to the side affects noted for most current medications,
the subjects in the University of Connecticut study and
individuals consuming the MaxWLX™ blend for more than one year
have reported very nominal side affects. The most frequent comment
is nominal gastrointestinal distress. However, these side effects
were not substantial enough to require the individuals to come off
the product -- unlike the medications. This provides for an
individual to establish long-term weight loss management.
In summary, the current drug medications available to treat the
global obesity pandemic are few and offer modest success rates. In
addition, these medications have considerable side affects that
make the continued use of said drugs limiting. The safety profile
of the MaxWLX™ blend, and the preliminary efficacy results
obtained from the University of Connecticut study, underscore the
need to move MaxWLX™ into the main stream consumer channel as
rapidly as possible.
References
1. Bray GA and Ryan DH. Drug treatment of the overweight patient.
Gastroenterology, 2007, 132(6): 2239-52.
2. Padwal R, Kezouh A, Levine M, Etminan M. Long-term persistence
with orlistat and sibutramine in a population-based cohort. Int J
Obesity, 2007, April 10, epub
3. Anderson JW, Schwartz SM, Hauptman J, Boldrin M, Rossi M,
Bansal V, Hale CA. Low-dose ortlistat effects on body weight of
mildly to moderately overweight individuals: a 16-week, double
blind, placebo-controlled trial. Ann Pharmacother. 2007, 41(3):
529-30.
4. Dixon JB, Strauss BJ, Laurie C, O’brien PE. Changes in body
composition with weight loss: obese subjects randomized to
surgical and medical programs. Obesity 2007, 15(5): 1187-98.
---------------------------------------------
INFLUENCES OF A DIETARY SUPPLEMENT IN COMBINATION WITH AN
EXERCISE AND DIET REGIMEN ON ADIPOCYTOKINES AND ADIPOSITY IN WOMEN
WHO ARE OVERWEIGHT
Maren S. Fragala, William J. Kraemer, Jeff S. Volek, Barry A.
Spiering, Disa L. Hatfield, Jakob L. Vingren, Jen Yu Ho, Cassandra
E. Forsythe, Michael J. Puglisi, Jeffrey M. Anderson, Carl M.
Maresh. Human Performance Laboratory, Department of Kinesiology,
University of Connecticut, 2095 Hillside Road, Gampel Pavilion,
University of Connecticut, Storrs, CT, 06269- 1110
The influence of a high, viscosity polysaccharide dietary
supplement on adipocytokine and regional body composition
responses to a weight loss program was examined. Twenty-two women
(Supplement group (S) (n=11): age= 36.8±7.2 y; weight=87.4 ±6.1
kg; % body fat= 43.6±7.1); Placebo group (P) (n=11): age =38.3±6.8
y; weight = 88.3±7.2 kg; % body fat=44.2±8.2) completed an 8-week
placebo-controlled, double-blind study consisting of a caloric
restricted diet and cardiovascular exercise. Body composition and
serum insulin, leptin, and adiponectin were assessed at pre-,
mid-, and post-intervention.
From pre- to post-intervention, significant decreases (p<0.05) were
observed for body weight (S: 87.4±6.1 to 78.2±3.4 kg; P: 88.3±7.2
to 82.9±4.1 kg) (p<0.05 S vs P), % body fat (S: 43.6±7.1 to
36.2±4.4; P:44.3±8.2 to 40.9±4.3) (p<0.05 S vs P), leptin (S:
28.2±6.1 to 16.3±3.4 μg•ml-1: P: 29.3±9.1 to 19.7±3.3 μg•ml-1)
(p<0.05 S vs P), and insulin (S: 7.2±2.2 to 5.4±2.4 mU•L-1; P:
7.7±2.2 to 5.2±2.7 mU•L-1). Serum adiponectin increased (p<0.05)
(S: 12.2±3.1 to 26.2±3.4 μg•ml-1: 12.6±4.2 to 21.7±4.3 μg•ml-1)
(p<0.05 for S vs P).
Data indicated the
dietary supplement used during an 8-week weight loss/exercise
program exhibited favorable effects on adipocytokines and regional
body composition.
Want To Try MaxWLX
For Yourself? Click Here!
Click here to social bookmark
this page!
* Important Notice: These statements have not been evaluated by
the Food and Drug Administration.
These products are not intended for use in the treatment of any
disease.
|
